Ingevity Corp annual report, FY2023

Открыть документ

Ingevity Corporation (NYSE: NGVT) — Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2023. This is an annual report; the filing text does not provide a clear standalone fourth-quarter income statement or cash-flow summary.

Business context

Ingevity makes specialty chemicals and activated-carbon products across Performance Materials, Performance Chemicals, and Advanced Polymer Technologies (APT). In 2023, it separated APT from Performance Chemicals for segment reporting. The company also began repositioning Performance Chemicals toward road technologies and other higher-margin products, while reducing or exiting certain industrial-specialties markets.

Financial performance

  • Revenue: $1.692 billion, up 1.4% from $1.668 billion in 2022. Favorable price and mix added $142.3 million, offset by a $106.3 million volume decline and $12.2 million of unfavorable currency impact.
  • Profit and margins: Gross profit was $471.9 million versus $570.1 million; gross margin was approximately 27.9%, down from 34.2%. Net loss was $5.4 million (diluted loss per share $0.15), compared with net income of $211.6 million ($5.50 diluted EPS) in 2022.
  • Adjusted EBITDA: $396.8 million, down from $452.6 million. This is a non-GAAP measure; the filing reconciles it to GAAP net loss.
  • Cash flow and investment: Operating cash flow was $205.1 million, down from $313.4 million. Capital expenditures were $109.8 million, compared with $142.5 million. Investing cash outflow was $77.3 million; financing cash outflow was $99.9 million.
  • Liquidity: Cash and cash equivalents were $95.9 million at year-end, including $90.7 million held by foreign subsidiaries. Undrawn revolving-credit capacity was $259.5 million. Management expects operating cash flow, cash, and available borrowing capacity to fund planned operations and obligations for at least 12 months.
  • Debt: Total debt and finance-lease obligations were $1.473 billion before debt issuance costs, including $738.0 million under the revolver, $550.0 million of 3.88% senior notes due 2028, $101.1 million of finance leases, and $81.3 million under receivables securitization. Revolver borrowings carried a 6.36% weighted-average rate in 2023. The company reported covenant compliance.
  • Segments: Performance Materials revenue was $586.0 million and segment EBITDA $286.6 million; Performance Chemicals revenue was $902.1 million and segment EBITDA $65.7 million; APT revenue was $204.0 million and segment EBITDA $44.5 million.

Changes versus 2022

  • Revenue rose modestly, but gross profit fell $98.2 million as manufacturing costs increased $158.6 million, primarily due to crude tall oil (CTO) cost pressure; lower volume, inventory charges, and currency also weighed on results. Price and mix partly offset these pressures.
  • Performance Materials improved: revenue increased to $586.0 million from $548.5 million and segment EBITDA to $286.6 million from $252.2 million, aided by volume and pricing.
  • Performance Chemicals revenue rose to $902.1 million from $875.1 million, but segment EBITDA fell to $65.7 million from $160.4 million. Road Technologies revenue grew 53.3%, while Industrial Specialties revenue declined 16.0% amid weak demand and high CTO costs.
  • APT revenue declined to $204.0 million from $244.7 million on a 24% volume decrease, while segment EBITDA increased to $44.5 million from $40.0 million, helped by pricing, mix, and lower input costs.
  • Restructuring and other charges increased to $170.2 million from $13.8 million. Interest expense rose to $93.3 million from $61.8 million, principally reflecting higher debt levels and interest rates.

Outlook, commentary, and material risks

  • 2024 guidance: Net sales of $1.40–$1.55 billion and Adjusted EBITDA of $365–$390 million. Management expects improved automotive volumes, continued Road Technologies growth, and APT demand recovery in the second half, while noting Performance Chemicals’ repositioning and elevated CTO costs. CTO cost pressure is expected to ease in the second half. The company did not provide a reconciliation of projected Adjusted EBITDA to GAAP net income.
  • Restructuring: Management estimates approximately $280 million of charges for the Performance Chemicals repositioning, including about $180 million asset-related, $15 million employee-related, and $85 million other restructuring costs. Approximately $180 million is expected to be non-cash; most non-cash charges and 50–60% of cash charges were expected in 2024. DeRidder was expected to close by the end of the first half of 2024. The actions target historical end uses representing approximately $300 million of net sales.
  • CTO exposure: CTO represented approximately 26% of consolidated cost of sales and 51% of raw-material purchases in 2023. The company expects to buy excess contracted CTO through October 2025 and estimates potential incremental 2024 resale losses of $30–$80 million at then-current market rates. A 10% unhedged increase in CTO prices would have increased 2023 cost of sales by approximately $31.6 million.
  • Other operating exposures: WestRock’s North Charleston mill closure required Ingevity to replace shared services; the company incurred $14.8 million in 2023 and expected another $3–$5 million in 2024. Risks also include supply-chain and transportation disruption, customer and end-market cyclicality, foreign exchange, interest rates, and manufacturing interruptions.
  • Contingency: The company accrued $85.0 million for the trebled BASF jury verdict and began accruing post-judgment interest after judgment was entered in May 2023. The year-end litigation accrual was $87.4 million. Ingevity intends to appeal; BASF may seek attorneys’ fees and costs, and final resolution could take up to 24 months.
  • Goodwill and controls: Despite a 2023 triggering event at Performance Chemicals, management recorded no goodwill impairment after its interim and annual tests. The auditor identified this assessment as a critical audit matter. Management and the auditor concluded internal control over financial reporting was effective at year-end; the financial statements received an unqualified audit opinion.

Most important facts for investors to verify

  • Whether Performance Chemicals’ repositioning delivers the expected profitability improvement and whether closure charges and timing remain within estimates.
  • Actual CTO contract volumes, resale prices, and losses compared with the estimated $30–$80 million 2024 range.
  • Progress in replacing North Charleston shared services and any effects on production, costs, or capital needs.
  • Performance against 2024 sales and Adjusted EBITDA guidance, including the assumed second-half recovery and CTO-cost moderation.
  • Developments in the BASF appeal, interest, and any attorneys’ fees or costs beyond the year-end accrual.
  • Debt reduction, interest expense, covenant headroom, and liquidity after restructuring spending, capital expenditures, and share repurchases.